Literature DB >> 23480748

Systemic therapy for locally advanced and metastatic cholangiocarcinoma.

Aumkhae Sookprasert1, Jarin Chindaprasert, Kosin Wirasorn.   

Abstract

Cholangiocarcinoma, the typical bile duct epithelium neoplasm, is most commonly reported in the Northeast of Thailand. Surgical intervention is the only possible curative treatment in the early stage of disease. Unfortunately, most patients are advanced at the time of diagnosis and not appropriate for curative surgical treatment. The prognosis of advanced CCA is extremely poor and chemotherapy is the only approved treatment for this stage of disease. This article reviews the state-of-art chemotherapy for locally advanced or metastatic cholangiocarcinoma.

Entities:  

Mesh:

Year:  2012        PMID: 23480748

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.

Authors:  Sirinapha Klungsaeng; Veerapol Kukongviriyapan; Auemduan Prawan; Sarinya Kongpetch; Laddawan Senggunprai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-23       Impact factor: 3.000

2.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

3.  Inhibition of growth and migration of cholangiocarcinoma cells by pamidronate.

Authors:  Benjaporn Buranrat; Auemduan Prawan; Laddawan Senggunprai; Veerapol Kukongviriyapan
Journal:  Exp Ther Med       Date:  2019-09-23       Impact factor: 2.447

4.  Frailty Syndrome in Biliary Tract Cancer Patients: Prevalence and Associated Factors

Authors:  Panita Limpawattana; Kosin Wirasorn; Aumkhae Sookprasert; Kittisak Sawanyawisuth; Attapol Titapun; Vor Luvira; Narong Khuntikeo; Jarin Chindaprasirt
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

5.  Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.

Authors:  Wunchana Seubwai; Kulthida Vaeteewoottacharn; Ratthaphol Kraiklang; Kazuo Umezawa; Seiji Okada; Sopit Wongkham
Journal:  Oncol Res       Date:  2016-01-21       Impact factor: 5.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.